2026: The FDA issued warning letters to clinics marketing unapproved exosome 'biologics' for hair loss — a reminder that buzzy in-clinic injectables can run ahead of the evidence and the law. 2025: Clascoterone 5% (Breezula) Phase 3 results supported moving toward an FDA filing; if approved it would be the first genuinely new mechanism against pattern hair loss in three decades. Also in 2025, deuruxolitinib (Leqselvi) launched in the US for severe alopecia areata, joining baricitinib and ritlecitinib in the JAK-inhibitor class.
2025: A review of roughly 84,000 people linked GLP-1 weight-loss drugs (Ozempic, Wegovy, Mounjaro) to about 3.4 times higher reported hair loss — almost always temporary telogen effluvium from rapid weight loss, not the drug poisoning follicles. 2024: The FDA approved deuruxolitinib for severe alopecia areata, and PP405 — which targets hair-follicle stem-cell metabolism — reported encouraging Phase 2a data. The throughline: real progress is coming, but today's proven treatments still work best started early.
Try the free self-check →Sources: AGA review (CCID) ↗
FAQ
How often is this updated?
We revise it as meaningful news lands — new approvals, major trial readouts or safety signals — and date each entry so you can see how current it is.
Does a new drug in the news mean I should wait to treat?
Usually not. Most pipeline drugs are years from pharmacies, and proven treatments work best started early. Starting now and switching later loses nothing.
Explore more
⚠️ When to see a doctor — don’t self-treat
- Sudden patchy or circular bald spots
- Redness, scaling, pus, pain or itch (possible scarring alopecia — treat urgently)
- Broken hairs or rapid loss
- Loss with body-wide signs (weight loss, fatigue, cycle changes, acne, extra hair)
- Loss right after a new medication
- Any hair loss in a child